Alcon presents Academy research. Alcon stock gains 1.17 percent

Published on 10/09/2026 at 12:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alcon posted USD 2.82 billion revenue and USD 0.84 adjusted EPS in Q2. Alcon stock costs EUR 57.01 on October 9, 2026 after EUR 56.35.

Key points in brief

Alcon presented dry-eye, contact-lens and eye-care research at Academy 2026 on September 29, 2026.
Second-quarter 2026 revenue reached USD 2.82 billion, while adjusted earnings per share came in at USD 0.84 versus USD 0.77 consensus.
The Lang & Schwarz quote was EUR 57.01 on October 9, 2026, up 1.17 percent from EUR 56.35.
Barclays initiated coverage at Equal Weight with a USD 70.00 price target on October 6, 2026.

Financial editorial photography of glowing trading monitors. Screens display EYE CARE, OPHTHALMOLOGY sector data, SIX SWISS EXCHANGE text with upward trending candlestick charts, green on dark blue, shallow depth of field — Alcon CH0432492467: Handelsterminals zeigen EYE CARE, OPHTHALMOLOGY und SIX SWISS EXCHANGE mit steigenden Charts, Illustration mit AI erstellt.

Alcon (ISIN CH0432492467) was trading at EUR 57.01 at Lang & Schwarz on October 9, 2026 at 12:10 p.m. CEST, up 1.17 percent versus its prior close. The company had announced on September 29, 2026 that it would present new research at Academy 2026, including studies on dry eye disease, contact lenses and lens care, according to Alcon.

Three milestones shaped the year

On May 5, 2026, Alcon reported revenue of USD 2.65 billion for the quarter ended March 31, 2026, according to Earnings Today. The same earnings history records second-quarter revenue of USD 2.82 billion for the quarter ended June 30, 2026, reported on August 10, 2026.

On September 29, 2026, Alcon said Academy 2026 would feature new dry-eye research, contact-lens studies and demonstrations of Voyager DSLT, Valeda PBM and MARLO. The company also identified booth 712 for the event, giving the research program a concrete commercial setting.

What does Q2 mean for earnings?

The second-quarter result combined USD 2.82 billion of revenue with adjusted earnings per share of USD 0.84, versus USD 0.77 consensus. That is a 9.09 percent beat calculated against the consensus figure, while revenue exceeded the USD 2.77 billion estimate by 1.80 percent, according to Earnings Today.

The earnings mix matters because the reported quarter also showed USD 510.0 million of operating cash flow. For investors, the combination of product launches, clinical evidence and above-consensus adjusted earnings gives the Academy announcement a measurable operating backdrop rather than a standalone promotional message.

Barclays sets a USD 70 target

Barclays initiated coverage of Alcon on October 6, 2026 with an Equal Weight rating and a USD 70.00 price target, according to Markets Insider. The analyst expected stabilizing fundamentals in 2027 to improve investor sentiment, while the neutral rating keeps the target from being read as an outright bullish call.

Next report arrives November 10

Alcon's next scheduled earnings report is November 10, 2026, according to Earnings Today. The date gives investors the next formal checkpoint for revenue growth, adjusted earnings and the commercial contribution from the company's eye-care portfolio.

Stock rises with a measurable backdrop

The Lang & Schwarz quote stood at EUR 57.01 on October 9, 2026 at 12:10 p.m. CEST, up 1.17 percent versus the prior close of EUR 56.35. On SIX SX, Alcon traded at CHF 52.76 at 9:28 a.m. CEST on October 9, 2026, according to finanzen.ch. The further course of trading is shown by the continuously updated real-time quote of Alcon stock.